New Drug Shows Promising Results in Fight Against Alzheimer's
Video Credit: Wibbitz Top Stories - Duration: 01:31s - Published
New Drug Shows Promising Results in Fight Against Alzheimer's
New Drug Shows , Promising Results in Fight Against , Alzheimer's.
BBC reports that a new drug has been
hailed as a turning point in the battle
against Alzheimer's disease.
.
A global trial confirmed that
donanemab, an antibody medicine,
can slow cognitive decline.
A global trial confirmed that
donanemab, an antibody medicine,
can slow cognitive decline.
This is truly a turning point in
the fight against Alzheimer's
and science is proving that it is
possible to slow down the disease, The Alzheimer's Society, via BBC.
BBC reports that the medicine proved
effective in the early stages of the disease
at clearing protein buildup in the brain.
.
The trials suggest that the medication slowed
the pace of the disease by about a third, giving
patients more time to retain their mental capacities.
Eli Lilly produces donanemab, which works the same
way as competitor Eisai and Biogen's lecanemab,
which made global headlines by slowing the disease.
Eli Lilly produces donanemab, which works the same
way as competitor Eisai and Biogen's lecanemab,
which made global headlines by slowing the disease.
BBC points out that while the results
are promising, these medications are
not a risk-free form of treatment.
Up to a third of patients
reportedly experienced , brain swelling.
.
Two volunteers, and potentially
a third, died after developing
dangerous swelling in the brain.
Regulators in Europe recently rejected another
Alzheimer's drug, aducanumab, citing safety
concerns and questions regarding the drug's efficacy
Newly-Discovered Gene Variant , Could Help Prevent or Treat , Alzheimer's Disease.
'Newsweek' reports that scientists have uncovered
a genetic variant that has the potential to reduce
the odds of developing Alzheimer's by as much as 70%.
The discovery could reportedly lead to new methods to
effectively treat or prevent the disease which impacts
approximately 5.8 million people in the United States alone.
Some genetic variants have been found to have an
association with an increased likelihood of developing
the disease, while other variants offer protection. .
A team from Columbia University found that
genes involved with the production of fibronectin
play a crucial role in developing Alzheimer's.
Healthy individuals usually only have fibronectin present
in small amounts along their blood-brain barrier, while
those with Alzheimer's have much higher quantities.
It's a classic case of too much
of a good thing. It made us think
that excess fibronectin could be
preventing the clearance of [abnormal
protein clumps] from the brain, Caghan Kizil, co-leader of the study and professor of
neurological sciences at Columbia University's Vagelos
College of Physicians and Surgeons, via 'Newsweek'.
The team believes that methods aimed at reducing
fibronectin could play a crucial role in developing
new treatments and preventative measures. .
Anything that reduces excess
fibronectin should provide some
protection, and a drug that does
this could be a significant step
forward in the fight against
this debilitating condition, Caghan Kizil, co-leader of the study and professor of
neurological sciences at Columbia University's Vagelos
College of Physicians and Surgeons, via 'Newsweek'.
Our findings suggest that...
we may be able to develop new
types of therapies that mimic
the gene's protective effect
to prevent or treat the disease, Caghan Kizil, co-leader of the study and professor of
neurological sciences at Columbia University's Vagelos
College of Physicians and Surgeons, via 'Newsweek'.
The Columbia University team's
findings were published in the
journal 'Acta Neuropathologica.'
Credit: Wibbitz Top Stories Duration: 01:31Published
New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .
NBC reports that patients taking
Novo Nordisk's obesity treatment maintain
an average of 10% weight loss over four years.
The news potentially boosts the
drugmaker's push for Wegovy to be
covered by insurers and governments. .
The company submitted long-term
findings at the European Congress
on Obesity in Venice, Italy. .
This is the longest study
we’ve conducted so far of
semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.
We see that once the majority
of the weight loss is accrued,
you don’t go back and start
to increase in weight
if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.
According to another analysis published by
the drugmaker, approximately 17% of trial participants stopped using the treatment
due to side effects like nausea. .
The costly treatment ranges from $200
to nearly $2,000 per month in the ten
countries where the drug is available.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
Rival Eli Lilly launched its drug
Zepbound in the United States
in December of 2023. .
Neither drugmaker has managed
to produce enough of the
treatment to meet surging demand
Credit: Wibbitz Top Stories Duration: 01:31Published
Latest Weight-Loss Drug , Faces Shortages .
The United States Food and Drug Administration
(FDA) says that high demand has left the latest
weight-loss drug, Zepbound, in short supply.
'Newsweek' reports that the Eli Lilly product
is expected to experience limited availability
through Q2 of 2024 as surging demand has
outpaced the manufacturer's expectations.
We have experienced
an unparalleled surge in
demand for our type 2
diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.
We recognize this situation may
cause a disruption in peoples'
treatment regimens and are
working with purpose and
urgency to help meet
the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.
The FDA said that Novo Nordisk's weight-loss
drug, Wegovy, is also experiencing a
widespread supply shortage with no end
in sight for the drug's limited availability.
By the year 2030, 'Newsweek' reports
that the weight-loss drug market is
expected to grow to about $100 billion.
We expect our investments
in manufacturing and supply
capacity to progressively increase
production of our medicines
throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.
Over the past year, manufacturer Eli Lilly
has already seen share prices rise over 102%.
The company has announced plans
to expand operations to meet increased
demand for its incretin products which are
used in the firm's diabetes treatments. .
Incretin mimics gut hormones
that regulate blood sugar
while also suppressing appetite
Credit: Wibbitz Top Stories Duration: 01:30Published
![Newly-Discovered Gene Variant Could Help Prevent or Treat Alzheimer's Disease [Video]](https://video.newsserve.net/300/v/20240410/1372339152-Newly-Discovered-Gene-Variant-Could-Help-Prevent-or.jpg)
![New Analysis Suggests Long-Term Effectiveness for Wegovy Users [Video]](https://video.newsserve.net/300/v/20240514/1375493648-New-Analysis-Suggests-Long-Term-Effectiveness-for-Wegovy.jpg)
![Latest Weight-Loss Drug Faces Shortages [Video]](https://video.newsserve.net/300/v/20240418/1373021964-Latest-Weight-Loss-Drug-Faces-Shortages.jpg)
![New Alzheimer's treatment: Donanemab drug seen as turning point in fight against disease [Video]](https://video.newsserve.net/300/v/20230718/1355516366-New-Alzheimer-treatment-Donanemab-drug-seen-as.jpg)
